|
|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/34471
| Title: | CARDIOVASCULAR COMORBIDITIES IN PATIENTS WITH GOUT |
| Authors: | Varanita, Ion |
| Keywords: | gout;hyperuricemia;cardiovascular comorbidities |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Varanita, Ion. CARDIOVASCULAR COMORBIDITIES IN PATIENTS WITH GOUT. In: MedEspera 2026, p. 656. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. In recent decades, gout has become an increasingly important public health problem, due to its increasing prevalence and frequent association with multiple concomitant systemic diseases, especially cardiovascular, metabolic and renal. The link between hyperuricemia and cardiovascular pathology is explained by complex mechanisms, such as endothelial dysfunction, oxidative stress, vascular inflammation and activation of the renin-angiotensin-aldosterone system. These processes contribute to the development of arterial hypertension, ischemic cardiopathy and other cardiovascular comorbidities. Aim of study. To evaluate cardiovascular comorbidities in patients diagnosed with gout. Methods and materials. A retrospective study was conducted based on the analysis of medical records of patients diagnosed with gout (ACR/EULAR 2015) from the Rheumatology and Arthrology departments of the Republican Clinical Hospital "Timofei Moşneaga" between 2025 and 2026. The study group included 50 patients, of whom 43 were men (86%) and 7 were women (14%), the mean age of the patients was 67 years (95% CI, 64.9- 69.1 years), with limits between 46 and 88 years, the mean age at the onset of the disease was 39.5 years (95% CI, 37.5-41.5 years), the duration of the disease at the time of inclusion in the study was 14.5 years (95% CI, 13.3-15.7 years), with limits between 2 and 27 years. The following laboratory parameters were assessed: erythrocyte sedimentation rate, serum uric acid, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, urea, creatinine and instrumental investigations: ECG, ECOCS+Doppler, USG of internal organs, radiography. Results. Hypertension was recorded in 41 patients (82%) (95% CI, 31.4%-50.5%), the presence of dyslipidemia was identified in 39 patients (78%) (95% CI, 29.4%-48.6%), the presence of hypertensive cardiopathy was established in 38 patients (76%) (95% CI, 28.5%-47.5%), heart failure was diagnosed in 4 patients (8%) (95% CI, 0.2%-7.8%), and mixed cardiopathies were present in 5 patients (10%) (95% CI, 0.7%-9.3%). In one case (2%), bilateral carotid artery occlusion and stenosis was diagnosed. Conclusions. The results of the study highlight an increased frequency of cardiovascular comorbidities in patients with gout, the most common being hypertension. Early identification and careful monitoring of cardiovascular comorbidities in patients with gout are essential for optimizing therapeutic management and reducing the risk of long-term cardiovascular complications. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/34471 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|